A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma

Documenti analoghi

• A Fatal Case of Immune Checkpoint Inhibitor‐Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma
  di: Matthew T. Newman, et al.
  Pubblicazione: (2024)
• Incidence Status and Factors Associated With Tyrosine Kinase Inhibitor‐Induced Hypertension in Patients With Renal Cell Carcinoma
  di: Satoru Nakanishi, et al.
  Pubblicazione: (2025)
• Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report
  di: Takahiro Sasaki, et al.
  Pubblicazione: (2025)
• Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF ‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF / MEK Inhibitors: A Case Report
  di: Akira Shibata, et al.
  Pubblicazione: (2026)
• TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer
  di: Zenta Seto, et al.
  Pubblicazione: (2025)